LT3463457T - Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą - Google Patents

Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą

Info

Publication number
LT3463457T
LT3463457T LTEPPCT/US2017/035492T LTUS2017035492T LT3463457T LT 3463457 T LT3463457 T LT 3463457T LT US2017035492 T LTUS2017035492 T LT US2017035492T LT 3463457 T LT3463457 T LT 3463457T
Authority
LT
Lithuania
Prior art keywords
nivolumab
blockade
lymphoma
refractory hodgkin
hodgkin
Prior art date
Application number
LTEPPCT/US2017/035492T
Other languages
English (en)
Lithuanian (lt)
Inventor
Benedetto FARSACI
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59067911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3463457(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3463457T publication Critical patent/LT3463457T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2017/035492T 2016-06-02 2017-06-01 Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą LT3463457T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344880P 2016-06-02 2016-06-02
PCT/US2017/035492 WO2017210453A1 (en) 2016-06-02 2017-06-01 Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma

Publications (1)

Publication Number Publication Date
LT3463457T true LT3463457T (lt) 2023-09-11

Family

ID=59067911

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2017/035492T LT3463457T (lt) 2016-06-02 2017-06-01 Pd-1 blokada su nivolumabu gydant atsparią hodžkino limfomą

Country Status (17)

Country Link
US (3) US11083790B2 (cg-RX-API-DMAC10.html)
EP (2) EP3463457B1 (cg-RX-API-DMAC10.html)
JP (3) JP7175198B2 (cg-RX-API-DMAC10.html)
KR (2) KR20230038318A (cg-RX-API-DMAC10.html)
CN (1) CN109475633A (cg-RX-API-DMAC10.html)
DK (1) DK3463457T3 (cg-RX-API-DMAC10.html)
ES (1) ES2954139T3 (cg-RX-API-DMAC10.html)
FI (1) FI3463457T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20230864T1 (cg-RX-API-DMAC10.html)
HU (1) HUE062398T2 (cg-RX-API-DMAC10.html)
LT (1) LT3463457T (cg-RX-API-DMAC10.html)
PL (1) PL3463457T3 (cg-RX-API-DMAC10.html)
PT (1) PT3463457T (cg-RX-API-DMAC10.html)
RS (1) RS64388B1 (cg-RX-API-DMAC10.html)
SI (1) SI3463457T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202300290T1 (cg-RX-API-DMAC10.html)
WO (1) WO2017210453A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383464B (es) 2015-07-13 2025-03-14 Cytomx Therapeutics Inc Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
HUE062398T2 (hu) 2016-06-02 2023-10-28 Bristol Myers Squibb Co PD-1 blokád nivolumabbal refrakter Hodgkin limfómában
MX390955B (es) 2016-06-02 2025-03-19 Seagen Inc Uso de un anticuerpo anti-pd-1 en combinación con un anticuerpo anti-cd30 para el tratamiento de linfoma.
US12668635B1 (en) 2017-11-21 2026-06-30 Arcus Biosciences, Inc. Methods of treating solid tumors using an anti-PD-1 antibody or a fragment thereof
WO2019140150A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
CN113164599B (zh) * 2018-12-24 2023-08-01 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
KR20210146348A (ko) * 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
WO2025136845A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Methods of treating a patient with a pd-1 antagonist

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US20060032289A1 (en) 2004-08-11 2006-02-16 Pinnaduwage Lal A Non-optical explosive sensor based on two-track piezoresistive microcantilever
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CA3175360C (en) 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
HUE062398T2 (hu) 2016-06-02 2023-10-28 Bristol Myers Squibb Co PD-1 blokád nivolumabbal refrakter Hodgkin limfómában

Also Published As

Publication number Publication date
JP2025020119A (ja) 2025-02-12
US20250134996A1 (en) 2025-05-01
EP3463457A1 (en) 2019-04-10
KR20190015377A (ko) 2019-02-13
PT3463457T (pt) 2023-09-07
US20190290757A1 (en) 2019-09-26
JP2023025012A (ja) 2023-02-21
JP7568698B2 (ja) 2024-10-16
RS64388B1 (sr) 2023-08-31
JP2019517504A (ja) 2019-06-24
PL3463457T3 (pl) 2023-08-21
HRP20230864T1 (hr) 2023-11-10
FI3463457T3 (fi) 2023-09-12
US20220025049A1 (en) 2022-01-27
EP4248990A2 (en) 2023-09-27
HUE062398T2 (hu) 2023-10-28
KR20230038318A (ko) 2023-03-17
JP7175198B2 (ja) 2022-11-18
WO2017210453A1 (en) 2017-12-07
ES2954139T3 (es) 2023-11-20
SI3463457T1 (sl) 2023-09-29
EP3463457B1 (en) 2023-06-28
US11083790B2 (en) 2021-08-10
CN109475633A (zh) 2019-03-15
DK3463457T3 (da) 2023-10-02
EP4248990A3 (en) 2024-01-03
SMT202300290T1 (it) 2023-11-13

Similar Documents

Publication Publication Date Title
SMT202300290T1 (it) Blocco di pd-1 con nivolumab nel linfoma di hodgkin refrattario
IL269461B (en) Cytidine-5-carboxamide modified nucleotide preparations and related methods
PL3067380T3 (pl) Kompozycja poliwęglanowa i zawierający ją wyrób
ZA201507314B (en) Refractory batch and use thereof
PL3177682T3 (pl) Kompozycja utwardzalna i formowany wyrób zawierający kompozycję
GB201512640D0 (en) Improvements in or relating to closures
PT3632202T (pt) Locais genéticos associados a fertilidade acrescida em milho
GB201511915D0 (en) Improvements in or relating to closures
SG11201507941RA (en) Pmma provided with impact resistance and having improved optical properties
EP3175723A4 (en) Men&#39;s underwear
ZA201704866B (en) Protective articles
GB201409413D0 (en) Polymer composition and heat -shrinkable article
PL3187258T3 (pl) Ulepszenia w reaktorach lub z nimi związane
SG11201610296YA (en) Acrylic composition with olefin block copolymer
ZA201703123B (en) Combination long acting compositions and methods for hepatitis c
SG11201510734WA (en) A polyethylene composition and process for polymerizing the same
EP3154996A4 (en) Protecting groups for &#34;z nucleotide&#34; and methods thereof
GB201617176D0 (en) Improvements in or relating to closures
TWI563553B (en) Using nano-spheres or micro-spheres and laser to fabricate substrate with nanostructures
SI3191080T1 (sl) Parenteralni sestavki in njihova uporaba
GB201615505D0 (en) CR 2032/CR 2016/CR 2025/ All 3 volt batterys
GB201309694D0 (en) Artist&#39;s implement
GB201412638D0 (en) Artist&#39;s implement
GB201610289D0 (en) Improvements in or relating to closures
GB201504973D0 (en) Protective articles